February 18, 2022 -- Discovery Life Sciences is expanding its good manufacturing practices (GMP)-compliant, clinical-grade product portfolio with the launch of Discovery Cryo Leukopaks.
Discovery has optimized and controlled cryopreservation protocols to achieve high-quality performance specifications that support GMP-compliant manufacturing requirements and allow cell and gene therapy developers to seamlessly transition their advanced therapy processes, the company said in a press release.
Combined with Discovery's isolated immune cells, diseased human biospecimens, and multiomic biomarker service capabilities, Discovery's cell and gene therapy portfolio offers researchers and manufacturers a unique, integrated solution to streamline the advancement of new therapies from early research through to clinical manufacturing, the firm added.
Copyright © 2022 scienceboard.net